16.1 Introduction
Juvenile dermatomyositis (JDMS) is a rare inflammatory disorder affecting skin and muscle.
16.2 Epidemiology
JDMS can begin in adolescence; however, peak incidence is 5–10 years of age occurring 2–4 cases per million children each year. The male to female ratio is 1:2–5.
16.3 Clinical Findings

Heliotrope: violaceous discoloration of the upper eyelid

Gottron’s papules noted on the dorsal hands overlying the joints

JDMS calcinosis of the elbows
16.4 Laboratory
Laboratory evaluation shows elevated muscle enzymes (serum aldolase, AST, CPK, and LDH). Skin biopsies are nonspecific with perivascular inflammation.
MRI has been used for diagnosis and for monitoring disease activity. The T2, fc-T2 (fat corrected T2), and FF (fat fraction) measurements are helpful in JDMS to distinguish those MRI findings that may also be seen in other myopathies. EMG and muscle biopsy are less often used because of the invasiveness. Muscle biopsies when they are performed can be guided by MRI – since the muscle involvement can be unevenly distributed.
16.5 Treatment
The medications used most often for JDMS are glucocorticosteroids, methotrexate, cyclosporin A, and IVIG. Other immunosuppressive agents have also been used in more refractory cases. Biologics have occasionally been used. Sun protection and physical therapy are also recommended.
16.6 Prognosis
The mortality rate of JDMS is less than 2%. JDMS is generally not associated with malignancy (in contrast to adult DM), and an occult malignancy work-up is not recommended.